DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nplate (Romiplostim Subcutaneous) - Published Studies

 
 



Nplate Related Published Studies

Well-designed clinical trials related to Nplate (Romiplostim Subcutaneous)

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. [2011.07.07]

Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. [2011.07]

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. [2011.03.01]

Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). [2011]

Romiplostim or standard of care in patients with immune thrombocytopenia. [2010.11.11]

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. [2010.10.28]

Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). [2010]

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. [2009.10.29]

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. [2009.07]

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. [2009.02]

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. [2008.02.02]

Well-designed clinical trials possibly related to Nplate (Romiplostim Subcutaneous)

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. [2009.02]

Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. [2008]

Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. [2007.12]

Other research related to Nplate (Romiplostim Subcutaneous)

Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. [2012]

Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue. [2011.12.02]

Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. [2011.11]

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. [2011.10.20]

Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). [2011.09.09]

Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. [2011.07]

The development of romiplostim for patients with immune thrombocytopenia. [2011.03]

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. [2011.03]

Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). [2011.01]

Romiplostim. [2011]

[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura]. [2010.12]

Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim. [2010.08]

Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. [2010.07.14]

Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. [2010.07]

Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. [2010.07]

Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). [2010.06]

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. [2010.01.20]

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. [2009.09]

Romiplostim in chronic immune thrombocytopenic purpura. [2009.09]

A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. [2009.09]

Romiplostim: a novel thrombopoiesis-stimulating agent. [2009.05.01]

Romiplostim management of immune thrombocytopenic purpura. [2009.05]

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. [2009.03.05]

Romiplostim: a second-generation thrombopoietin agonist. [2009.03]

Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. [2009.03]

Degarelix. [2009]

Romiplostim. [2008.11]

Other possibly related research studies

Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. [2009]

New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. [2009.06]

Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia. [2009.02]

Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. [2009.01]

New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. [2009.05.02]

Chronic immune thrombocytopenic purpura. New agents. [2009.01]

New options after first-line therapy for chronic immune thrombocytopenic purpura. [2009.01.15]

The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. [2008.11]

[Novel medical treatment modalities in hematology] [2008.06.09]

The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. [2008.07]

Overview of thrombopoietic agents in the treatment of thrombocytopenia. [2008.02]

New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. [2008.02]

Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. [2008.01]

[New treatment methods for autoimmune thrombocytopenia] [2007.11.24]

New insights and therapeutics for immune-mediated thrombocytopenia. [2008.01]

New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. [2008.01]

A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. [2007.05]

Toxicities of the thrombopoietic growth factors. [2010.07]

Thrombopoietic agents in immune thrombocytopenia. [2010.07]

Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. [2010.08]

Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. [2010.01]

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? [2009]

Treatment of MDS: something old, something new, something borrowed... [2009]

New thrombopoietic growth factors. [2009]

Development of thrombopoietin receptor agonists for clinical use. [2009.07]

Thrombopoietin receptor agonists in the treatment of thrombocytopenia. [2009.09]

Review Article: Second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. [2010.06]

Gateways to clinical trials. [2007.11]

Hematopoietic growth factors in myelodysplastic syndromes. [2011.10]

TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. [2011.07.06]

Romiplostin may revert the thrombocytopenia in graft-versus-host disease. [2011.03]

Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics. [2011]

Current treatment options for primary immune thrombocytopenia. [2011.02]

[New treatment options for primary immune thrombocytopenia]. [2011.01.24]

Current status of thrombopoietic agents. [2010.04]

Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. [2010.12]

The management of peripheral blood cytopenias in systemic lupus erythematosus. [2010.12]

Thrombocytopenia in patients with myelodysplastic syndromes. [2010.07]

Biology and chemistry of thrombopoietic agents. [2010.07]

Current and future management options for myelodysplastic syndromes. [2010.07.30]

Thrombopoietic agents. [2010.07]

Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care? [2010.12]

Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. [2011.03]

Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. [2012]

TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. [2011]

Thrombopoietin receptor agonists in primary immune thrombocytopenia. [2013]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014